MEN-1 Syndrome

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.

1. Overview

Multiple Endocrine Neoplasia Type 1 (MEN-1) is an autosomal dominant inherited tumour predisposition syndrome characterized by the development of multiple endocrine and non-endocrine neoplasms. It is caused by germline mutations in the MEN1 tumour suppressor gene located on chromosome 11q13. [1,2]

The syndrome is classically remembered by the "3 Ps":

1. Parathyroid adenomas/hyperplasia (95%)
2. Pancreatic and duodenal neuroendocrine tumours (40-70%)
3. Pituitary adenomas (30-40%)

However, MEN-1 is a multi-system disorder with additional manifestations including adrenal tumours, thymic and bronchial carcinoids, and cutaneous lesions. [3]

---

2. Visual Summary Panel

MEN-1 vs MEN-2 Comparison

---

3. Epidemiology

• Prevalence: 1 in 30,000 population. [1]
• Inheritance: Autosomal Dominant with high penetrance (> 95% by age 40, approaching 100% by age 50). [5]
• De novo mutations: Account for approximately 10% of cases.
• Age of onset: Most patients develop first manifestation in 2nd-4th decade, but range extends from childhood to elderly.
• Gender: Equal male to female ratio.
• Geographic distribution: Worldwide, all ethnic groups affected.

Age-Related Penetrance

---

4. Molecular Genetics

The MEN1 Gene

• Location: Chromosome 11q13 (spanning 9 kb)
• Structure: 10 exons encoding a 610 amino acid protein called MENIN
• Function: MENIN is a nuclear protein functioning as a tumour suppressor through multiple mechanisms [6]:
  • Regulation of gene transcription (interacts with chromatin-modifying enzymes)
  • DNA repair pathways
  • Cell division control
  • Genome stability maintenance

Mutation Spectrum

Over 1,300 different germline mutations identified in MEN1 gene: [7]

• Frameshift mutations: 44% (insertions/deletions causing premature stop codons)
• Nonsense mutations: 13% (create stop codons)
• Missense mutations: 20% (single amino acid substitutions)
• Splice site mutations: 9%
• Large deletions: 5%
• Promoter mutations: Rare

Distribution: Mutations occur throughout the gene with no clear hotspots, though exons 2, 9, and 10 are most frequently affected.

Genotype-Phenotype Correlations

• Weak correlations exist: [8]

  • Mutations in exons 2, 9, 10 may associate with more aggressive pancreatic NETs
  • Missense mutations in the JunD interaction domain correlate with earlier onset pituitary adenomas
  • However, significant phenotypic variation occurs even within families carrying identical mutations

• Modifier genes and environmental factors likely influence disease expression.

Two-Hit Hypothesis (Knudson Model)

MEN-1 follows the classic tumour suppressor paradigm: [9]

1. First hit: Germline mutation in one MEN1 allele (inherited or de novo)
2. Second hit: Somatic loss of the wild-type allele in susceptible tissues (loss of heterozygosity - LOH)
3. Result: Complete loss of MENIN function triggers tumourigenesis

Clinical implication: All endocrine cells carry the germline mutation, but tumours develop stochastically where LOH occurs, explaining variable age of onset and organ involvement.

---

5. Pathophysiology

MENIN Protein Function

MENIN is a 610 amino acid nuclear scaffold protein with multiple cellular functions: [10]

1. Transcriptional Regulation

• Interacts with histone methyltransferases (MLL1/MLL2 complexes)
• Regulates expression of cyclin-dependent kinase inhibitors (p18, p27)
• Modulates HOX gene expression important for development

2. DNA Repair and Genomic Stability

• Participates in DNA damage response pathways
• Loss of MENIN leads to chromosomal instability
• Increased susceptibility to additional oncogenic mutations

3. Cell Cycle Control

• Suppresses cell proliferation through p18^INK4C and p27^KIP1 upregulation
• Loss of function removes G1/S checkpoint control
• Permits unchecked cell division in endocrine tissues

Organ-Specific Pathology

Parathyroid Glands

• Multiglandular hyperplasia affecting all four glands (asymmetric but universal) [11]
• Monoclonal expansion in each gland (independent LOH events)
• Differs from sporadic primary hyperparathyroidism (usually single adenoma)
• Progression: Hyperplasia → Adenoma (benign)
• Carcinoma is extremely rare (less than 1%)

Pancreatic and Duodenal NETs

• Multiple tumours are the rule (often > 20 microscopic lesions at autopsy)

• Most are non-functional (40-50%) but may grow large

• Functional tumours by frequency:

  • Gastrinomas (40%): Usually in duodenal wall, often multiple, 60% malignant potential [12]
  • Insulinomas (10%): Pancreatic, usually multiple unlike sporadic (90% single), 10% malignant
  • Glucagonomas, VIPomas, Somatostatinomas: Rare (less than 5% each)
  • PPomas (Pancreatic Polypeptide): Common but usually asymptomatic

• Malignancy risk: 20-25% for pancreatic NETs, higher for gastrinomas [13]

• Metastatic potential correlates with size (> 2cm threshold for increased risk)

Pituitary Adenomas

• Monoclonal adenomas arising from anterior pituitary
• Often larger and more invasive than sporadic counterparts [14]
• More resistant to medical therapy
• Distribution by type:
  • Prolactinomas: 60%
  • Non-functioning adenomas: 15%
  • GH-secreting: 10%
  • ACTH-secreting: 5%
  • Mixed: 10%

Adrenal Lesions

• Present in 20-40% of patients [15]
• Usually non-functioning cortical adenomas
• Rarely: cortisol-secreting (Cushing's), pheochromocytoma (rare, more MEN-2)

Carcinoid Tumours

• Thymic carcinoids: 2-8%, almost exclusively in males, highly malignant (30% mortality)
• Bronchial carcinoids: 5-10%, often multicentric, less aggressive than thymic
• Major cause of mortality in MEN-1 syndrome

Cutaneous Manifestations

• Angiofibromas (80%): Multiple facial papules, clinically similar to tuberous sclerosis
• Collagenomas (70%): Skin-colored papules/nodules
• Lipomas (30%): Subcutaneous, multiple
• Café-au-lait macules: Less common
• Pathogenesis: Loss of MENIN in dermal mesenchymal cells

---

6. Clinical Presentation

Diagnostic Criteria for MEN-1

A clinical diagnosis of MEN-1 is established when a patient meets one of the following criteria: [2]

Clinical MEN-1:

• At least two of the three principal MEN-1 tumours (parathyroid, pancreatic NET, pituitary adenoma)

Familial MEN-1:

• At least one principal MEN-1 tumour AND a first-degree relative with MEN-1

Genetic MEN-1:

• Identification of a pathogenic MEN1 germline mutation, regardless of clinical manifestations

1. Parathyroid Adenomas/Hyperplasia (95%)

Clinical Features:

• Usually the first manifestation (median age 20-25 years, range 8-80) [1]
• 90-95% of MEN-1 patients by age 50
• Presents 20-30 years earlier than sporadic primary hyperparathyroidism

Symptoms of Hypercalcaemia:

• Bones: Bone pain, osteoporosis, pathological fractures, osteitis fibrosa cystica
• Stones: Nephrolithiasis (25-30%), nephrocalcinosis, chronic kidney disease
• Abdominal Groans: Constipation, nausea, pancreatitis, peptic ulcer disease
• Psychic Moans: Depression, anxiety, cognitive impairment, fatigue
• Cardiac: Shortened QT interval, arrhythmias

Biochemistry:

• Serum Calcium: Elevated (usually 2.6-3.5 mmol/L; mild to moderate elevation)
• Ionized Calcium: More sensitive indicator
• Parathyroid Hormone (PTH): Elevated or inappropriately normal (should be suppressed with hypercalcaemia)
• Phosphate: Low or low-normal (PTH increases renal phosphate excretion)
• 24-hour Urinary Calcium: Elevated
• Alkaline Phosphatase: May be elevated with bone disease
• Vitamin D (25-OH): Often low (PTH increases 1-alpha-hydroxylase but substrate depleted)

Red Flags:

• Hypercalcaemic crisis (> 3.5 mmol/L): Confusion, polyuria, dehydration, cardiac arrhythmias - MEDICAL EMERGENCY

---

2. Enteropancreatic Neuroendocrine Tumours (30-70%)

A. Gastrinomas (40% of MEN-1 patients) [12]

Zollinger-Ellison Syndrome:

• Gastrin hypersecretion → Massive gastric acid output

Clinical Features:

• Peptic Ulcer Disease: Multiple, recurrent, refractory to standard therapy, unusual locations (jejunum)
• Diarrhea: Secretory (60% of patients), due to acid inactivation of pancreatic enzymes
• Esophageal reflux disease: Severe, erosive esophagitis
• Complications: GI bleeding, perforation, strictures

Location:

• 70% in duodenum ("gastrinoma triangle": bounded by junction of cystic/common bile duct, junction of D2/D3 duodenum, junction of neck/body pancreas)
• 25% in pancreas
• Multiple tumours common (60% in MEN-1 vs 20% sporadic)

Diagnosis:

• Fasting Serum Gastrin: Markedly elevated (> 1,000 pg/mL highly suggestive; normal less than 100)
• Gastric pH: less than 2.0 (confirms acid hypersecretion; rules out achlorhydria)
• Secretin Stimulation Test: Paradoxical rise in gastrin (> 200 pg/mL increase) - diagnostic
• Chromogranin A: Elevated (non-specific NET marker)

Natural History:

• 60% have metastases at diagnosis (vs 25% sporadic)
• Liver metastases most common
• Slow-growing but ultimately life-threatening

---

B. Insulinomas (10% of MEN-1 patients) [16]

Clinical Features:

• Whipple's Triad:

  1. Symptoms of hypoglycemia (confusion, sweating, palpitations, tremor, seizures)
  2. Documented low blood glucose (less than 2.5 mmol/L or less than 45 mg/dL)
  3. Relief of symptoms with glucose administration

• Symptoms occur during fasting (overnight, between meals, with exercise)

• Weight gain (patients eat to prevent symptoms)

• Neuropsychiatric manifestations (confusion, personality changes, seizures)

Diagnosis:

• 72-hour Fast: Gold standard
  • Measure glucose, insulin, C-peptide, proinsulin every 4-6 hours
  • Terminate when glucose less than 2.5 mmol/L with symptoms
• Biochemical findings:
  • Glucose: less than 2.5 mmol/L
  • Insulin: Inappropriately elevated (> 3 μU/mL when glucose less than 2.5)
  • C-peptide: Elevated (rules out exogenous insulin)
  • Proinsulin: Elevated
  • Insulin/Glucose ratio: > 0.3
• Imaging: Often small (less than 2cm), may require specialized imaging (see Investigations)

Malignancy: 10% in MEN-1 (vs 5% sporadic)

---

C. Other Pancreatic NETs

Glucagonoma (less than 2%):

• Necrolytic Migratory Erythema: Characteristic rash (erythematous patches, crusting)
• Diabetes mellitus (mild)
• Weight loss, anemia
• Diarrhea, venous thromboembolism
• Diagnosis: Serum glucagon > 500 pg/mL (normal less than 100)

VIPoma (Verner-Morrison Syndrome, WDHA) (less than 1%):

• Watery Diarrhea: Massive (> 3L/day), secretory
• Hypokalemia: Profound (less than 2.5 mmol/L)
• Achlorhydria: Gastric acid suppression
• Dehydration, acute kidney injury
• Diagnosis: Serum VIP > 75 pg/mL (normal less than 50)

Somatostatinoma (less than 1%):

• Diabetes mellitus
• Diarrhea, steatorrhea (inhibits pancreatic enzymes)
• Cholelithiasis (inhibits gallbladder contraction)
• Diagnosis: Serum somatostatin > 100 pg/mL

PPoma (Pancreatic Polypeptide-secreting) (20%):

• Usually non-functional (asymptomatic)
• Elevated serum Pancreatic Polypeptide (> 300 pg/mL)
• Discovered incidentally on imaging
• Used as screening marker (75% of MEN-1 pancreatic NETs secrete PP)

Non-Functional NETs (40-50%):

• No hormone hypersecretion syndrome
• Present with mass effect: Abdominal pain, jaundice (bile duct obstruction), weight loss
• Often larger at diagnosis (> 3-5cm)
• Higher malignancy risk due to delayed detection

---

3. Pituitary Adenomas (30-40%) [14]

Characteristics:

• Median age of diagnosis: 35-40 years
• Often larger (macroadenomas > 1cm in 85%) and more invasive than sporadic
• More resistant to medical therapy and somatostatin analogues

Prolactinomas (60%)

Clinical Features:

• Women: Galactorrhea, amenorrhea, oligomenorrhea, infertility, decreased libido
• Men: Erectile dysfunction, decreased libido, gynecomastia, infertility (often present later with larger tumours)
• Both: Mass effect (headaches, visual field defects if macroadenoma)

Biochemistry:

• Serum Prolactin: Elevated (degree proportional to tumour size)

  • 200 ng/mL (> 4,000 mU/L): Highly suggestive of prolactinoma

  • 50-200 ng/mL: May be prolactinoma or "stalk effect" from other mass
• Macroprolactin: Check to exclude assay artifact (biologically inactive)
• Hook effect: Falsely low prolactin with very large tumours (requires sample dilution)

GH-Secreting Adenomas (10%)

Acromegaly:

• Coarse facial features, frontal bossing, prognathism
• Large hands and feet (increase in ring/shoe size)
• Skin changes: Thick, oily, skin tags
• Organomegaly: Cardiomegaly, hepatosplenomegaly
• Arthropathy, carpal tunnel syndrome
• Hypertension, diabetes mellitus
• Sleep apnea, increased cancer risk (colon)

Biochemistry:

• IGF-1: Elevated, age and sex-adjusted (screening test)
• GH: Random GH not useful (pulsatile secretion)
• Oral Glucose Tolerance Test (OGTT): GH fails to suppress less than 1 μg/L (diagnostic)

ACTH-Secreting Adenomas (5%)

Cushing's Disease:

• Central obesity, moon facies, buffalo hump
• Purple striae, easy bruising, thin skin
• Proximal myopathy, bone loss
• Hypertension, diabetes, psychiatric disturbance

Biochemistry:

• 24-hour Urinary Free Cortisol: Elevated (> 3x upper limit normal)
• Late-night Salivary Cortisol: Elevated (loss of circadian rhythm)
• Low-dose Dexamethasone Suppression Test: Failure to suppress
• ACTH: Elevated or normal (pituitary source) vs suppressed (adrenal source)
• High-dose Dexamethasone Suppression Test: Suppression suggests pituitary (vs ectopic ACTH)
• CRH Stimulation Test: Rise in ACTH suggests pituitary

Non-Functioning Adenomas (15%)

• No hormone hypersecretion
• Present with mass effect:
  • Visual field defects: Bitemporal hemianopia (chiasm compression)
  • Headaches
  • Hypopituitarism: Multiple anterior pituitary hormone deficiencies
• Often gonadotroph origin (may secrete FSH/LH but clinically silent)

---

4. Adrenal Lesions (20-40%) [15]

• Cortical adenomas: Most common, non-functioning
• Cortisol-secreting adenomas: Cushing's syndrome (rare)
• Hyperplasia: Bilateral adrenal hyperplasia (uncommon)
• Pheochromocytoma: Very rare in MEN-1 (consider MEN-2 if present)
• Adrenocortical carcinoma: Extremely rare

Clinical Relevance:

• Most are incidental findings on surveillance imaging
• Require functional assessment if > 1cm
• Imaging characteristics to assess for malignancy risk

---

5. Carcinoid Tumours

Thymic Carcinoids (2-8%) [17]

• Almost exclusively in males (smoking may be risk factor)
• Median age: 40s
• Highly malignant: 30% mortality, metastasize to mediastinal nodes, lung, liver
• Often locally invasive at diagnosis
• Leading cause of death in male MEN-1 patients

Clinical Features:

• Often asymptomatic until advanced
• Chest pain, cough, superior vena cava syndrome
• Rarely functional (Cushing's syndrome from ectopic ACTH)

Bronchial Carcinoids (5-10%)

• Equal sex distribution
• Often multiple, peripheral
• Less aggressive than thymic carcinoids
• Carcinoid syndrome rare (5-HT secretion): Flushing, diarrhea, bronchospasm, valvular heart disease

---

6. Cutaneous Manifestations

Facial Angiofibromas (80%): [18]

• Multiple small (1-3mm) skin-colored to erythematous papules
• Distribution: Central face (nose, nasolabial folds, chin)
• Histology: Fibrovascular proliferation
• Differential: Tuberous sclerosis, multiple trichoepitheliomas

Collagenomas (70%):

• Skin-colored firm papules/nodules (2-10mm)
• Distribution: Trunk, extremities
• Histology: Accumulation of collagen bundles

Lipomas (30%):

• Subcutaneous, multiple, variable size
• Distribution: Trunk, extremities

Clinical Pearl: Cutaneous lesions may precede endocrine tumours and serve as diagnostic clue.

---

7. Clinical Examination

Systematic Approach in MEN-1 Suspect

1. General Inspection:

• Acromegalic features? (GH-secreting pituitary adenoma)
• Cushingoid features? (ACTH-secreting adenoma or adrenal tumour)
• Evidence of weight loss or cachexia? (Malignant NET)
• Surgical scars? (Previous parathyroid/pancreatic/pituitary surgery)

2. Face and Skin:

• Facial angiofibromas: Multiple small papules on central face
• Collagenomas: Skin nodules on trunk
• Lipomas: Palpable subcutaneous masses

3. Eyes and Visual Fields:

• Visual acuity: Reduced with optic chiasm compression
• Visual fields by confrontation: Bitemporal hemianopia (pituitary macroadenoma)
• Fundoscopy: Papilledema (raised ICP), optic atrophy

4. Thyroid:

• Palpate for thyroid nodules (uncommon in MEN-1, consider MEN-2 if medullary thyroid cancer)

5. Cardiovascular:

• Hypertension: Hyperparathyroidism, Cushing's, pheochromocytoma (rare)
• Arrhythmias: Hypercalcaemia (shortened QT on ECG)

6. Abdomen:

• Hepatomegaly: Metastatic NETs (liver most common site)
• Epigastric tenderness: Peptic ulcer disease (gastrinoma)
• Renal mass or tenderness: Nephrolithiasis

7. Musculoskeletal:

• Proximal myopathy: Cushing's syndrome
• Bone tenderness: Osteoporosis, pathological fractures (hyperparathyroidism)
• Large hands/feet: Acromegaly

8. Neurological:

• Cognitive assessment: Hypercalcaemia, hypoglycaemia
• Cranial nerves: Pituitary mass effect (III, IV, VI palsies)

---

8. Differential Diagnosis

Conditions Mimicking MEN-1

Multiple Endocrine Tumours:

• MEN-2A: RET mutation, medullary thyroid carcinoma, pheochromocytoma, hyperparathyroidism
• MEN-2B: RET mutation, medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus, mucosal neuromas
• MEN-4: CDKN1B mutation, similar to MEN-1 but rarer
• Familial Isolated Hyperparathyroidism (FIHP): MEN1 or CDC73 mutations
• Von Hippel-Lindau (VHL): Pancreatic NETs, pheochromocytoma, renal cell carcinoma, hemangioblastomas
• Neurofibromatosis Type 1: Pheochromocytoma, duodenal somatostatinoma

Sporadic Endocrine Tumours:

• Sporadic Primary Hyperparathyroidism: Single adenoma, older age, no family history
• Sporadic Pituitary Adenomas: Single lesion, no other endocrine tumours
• Sporadic Pancreatic NETs: Usually solitary

Facial Angiofibromas:

• Tuberous Sclerosis Complex (TSC): TSC1/TSC2 mutations, seizures, renal angiomyolipomas, cardiac rhabdomyomas
• Multiple Trichoepitheliomas: Benign skin tumours, no systemic features

---

9. Investigations

Genetic Testing

Indications: [2]

• Clinical diagnosis of MEN-1 (2 of 3 principal tumours)
• Single principal tumour with family history
• Single principal tumour at young age (less than 40 years for hyperparathyroidism, less than 30 for pituitary)
• Multiple pancreatic NETs
• First-degree relatives of confirmed MEN-1 patients

Method:

• Germline DNA sequencing of MEN1 gene (all 10 exons and promoter)
• Multiplex ligation-dependent probe amplification (MLPA) for large deletions
• Detection rate: 70-90% in familial cases, 65% in simplex cases

Interpretation:

• Pathogenic mutation identified → Genetic MEN-1 confirmed
• No mutation detected → Does not exclude MEN-1 (10-30% false negative rate)
  • Variant of uncertain significance (VUS): Requires family segregation studies
  • Deep intronic mutations not detected by standard sequencing
  • Mosaicism
  • Phenocopy (clinical MEN-1 without MEN1 mutation)

---

Biochemical Screening

For Confirmed or Suspected MEN-1 Patients:

Annually from age 5-8 years (or earlier if family mutation known): [2,19]

Additional Tests if Indicated:

• Glucagon: If necrolytic migratory erythema or diabetes
• VIP: If secretory diarrhea
• ACTH, 24-hr urinary free cortisol: If Cushing's features
• Metanephrines: If hypertension/pheochromocytoma suspected (rare)

Frequency:

• Annual screening for mutation carriers and clinical MEN-1
• Every 3 years from age 8 to 20, then annually for at-risk family members without confirmed mutation

---

Imaging Protocols

Parathyroid Imaging

Indications: Pre-operative localization (not for diagnosis)

• Sestamibi Scan (99mTc-MIBI): Sensitivity 40-60% in MEN-1 (multiglandular disease reduces sensitivity vs sporadic)
• Neck Ultrasound: Operator-dependent, identifies enlarged glands
• 4D CT Parathyroid: High-resolution, contrast-enhanced, multiphase
• MRI Neck: Alternative if CT contraindicated

Limitation: Negative imaging does not exclude disease. Bilateral neck exploration required in MEN-1.

---

Pancreatic Imaging [20]

Goal: Detect pancreatic and duodenal NETs

Modalities:

1. CT Pancreas (Multiphase with Pancreatic Protocol):

   • Sensitivity: 70-80% for lesions > 1cm, poor for less than 5mm
   • Arterial and portal venous phases
   • Assess liver for metastases

2. MRI Abdomen (with Gadolinium):

   • Sensitivity: 80-90% (superior to CT for small lesions)
   • T2-weighted, diffusion-weighted sequences
   • Preferred modality for surveillance

3. Endoscopic Ultrasound (EUS):

   • Highest sensitivity (90-95%) for pancreatic and duodenal NETs
   • Detects lesions less than 5mm
   • Allows biopsy for histological diagnosis
   • Recommended annually or biannually

4. Somatostatin Receptor Imaging:

   • 68Ga-DOTATATE PET/CT: Gold standard functional imaging
     • Sensitivity > 90% for well-differentiated NETs
     • Whole-body staging, detects metastases
     • Guides therapy (somatostatin analogues, PRRT)
   • 111In-Octreotide Scan (Octreoscan): Older technique, largely replaced by PET

Surveillance Frequency:

• MRI abdomen: Annually from age 10-20 (depending on protocol)
• EUS: Every 1-2 years from age 10-20
• 68Ga-DOTATATE PET/CT: At baseline, then as clinically indicated

---

Pituitary Imaging

MRI Pituitary (with Gadolinium):

• Modality of choice (sensitivity > 90%)
• Thin cuts through sella (1-2mm), coronal and sagittal views
• Assess: Tumour size, invasion (cavernous sinus, sphenoid), chiasm compression

Frequency:

• Every 3 years from age 5-10, then annually if prolactin elevated

---

Chest Imaging (Thymic/Bronchial Carcinoids) [17]

CT Chest (with Contrast):

• Detect thymic and bronchial carcinoids
• Thin cuts through anterior mediastinum

MRI Chest:

• Alternative if CT contraindicated

68Ga-DOTATATE PET/CT:

• Functional imaging for carcinoids

Frequency:

• CT chest every 1-2 years from age 15 (males) or 20 (females)
• More frequent in males due to higher thymic carcinoid risk

---

Surveillance Summary Protocol [19]

---

10. Management

Management requires multidisciplinary team coordination:

• Endocrinologist
• Endocrine Surgeon
• Gastroenterologist
• Medical Oncologist
• Clinical Geneticist
• Radiologist (interventional)

A. Parathyroid Disease Management [4,11]

Indications for Surgery:

• Symptomatic hypercalcaemia
• Serum calcium > 2.85 mmol/L (> 11.5 mg/dL)
• Complications: Nephrolithiasis, reduced eGFR, osteoporosis (T-score < -2.5), age less than 50

Surgical Options:

1. Subtotal Parathyroidectomy (3.5 Gland Resection):

   • Remove 3 glands + half of most normal-appearing gland
   • Leave ~50mg parathyroid remnant (marked with clip/suture)
   • Aim: Maintain normo- or mild hypocalcaemia post-op
   • Recurrence: 50% at 10 years, 80% at 20 years

2. Total Parathyroidectomy + Autotransplantation:

   • Remove all 4 glands
   • Mince and transplant 50mg into forearm brachioradialis muscle (15-20 pockets)
   • Advantage: Easier re-operation (forearm vs neck re-exploration)
   • Recurrence: Similar to subtotal

Intraoperative Considerations:

• Identify all 4 glands + ectopic locations (thymus, retroesophageal, intrathyroidal)
• Intraoperative PTH monitoring (> 50% fall at 10 min post-resection predicts cure)
• Cryopreserve parathyroid tissue for future autotransplant if needed

Post-Operative Management:

• Hungry Bone Syndrome: Severe hypocalcaemia 24-72 hours post-op
  • Mechanism: Rapid bone remineralization
  • Treatment: IV calcium gluconate infusion, high-dose oral calcium (3-6g/day), alfacalcidol/calcitriol
• Monitor calcium, PTH, magnesium, phosphate
• Long-term: Calcium + vitamin D supplementation

Medical Management (if surgery declined/poor candidate):

• Calcimimetics (Cinacalcet): Allosteric modulator of calcium-sensing receptor
  • Lowers serum calcium and PTH
  • Dose: 30-90mg twice daily
  • Does not cure, lifelong therapy required
  • Side effects: Nausea, hypocalcaemia

---

B. Pancreatic and Duodenal NET Management [12,13,20]

Risk Stratification:

---

1. Gastrinomas

Medical Management:

• High-dose Proton Pump Inhibitors (PPIs): First-line
  • Omeprazole 40-120mg/day (divided doses)
  • Lansoprazole 30-90mg/day
  • Titrate to basal acid output less than 10 mEq/hour
• H2-Receptor Antagonists: Less effective, second-line

Surgical Management:

• Indications: Localized disease, curative intent, symptomatic despite medical therapy
• Approach:
  • Duodenotomy with palpation/transillumination (duodenal gastrinomas often multiple)
  • Distal pancreatectomy if pancreatic gastrinoma
  • Enucleation of pancreatic lesions if safe
• Challenge: Multifocal disease, occult primary common
• Cure rate: 30-40% (vs 60% sporadic)

Metastatic Disease:

• Somatostatin analogues (octreotide, lanreotide): Control symptoms, slow progression
• Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE
• Chemotherapy (streptozocin + 5-FU, temozolomide + capecitabine)
• Hepatic-directed therapy (embolization, radiofrequency ablation)

---

2. Insulinomas

Medical Management:

• Diazoxide: Inhibits insulin release
  • Dose: 150-600mg/day
  • Side effects: Fluid retention, hirsutism, hyperglycemia
• Somatostatin Analogues: Variable efficacy, may worsen hypoglycemia (suppresses glucagon)
• Frequent meals: Prevent fasting hypoglycemia

Surgical Management:

• Treatment of choice (curative in 90%)
• Approach:
  • Enucleation for small (less than 2cm), superficial, benign-appearing lesions
  • Distal pancreatectomy for body/tail lesions
  • Pancreaticoduodenectomy (Whipple) for head lesions (rarely needed)
• Intraoperative:
  • Intraoperative ultrasound to localize
  • Blood glucose monitoring (rise indicates successful resection)
• Multiple insulinomas common in MEN-1 (vs 90% single in sporadic)

---

3. Non-Functional Pancreatic NETs [13]

Management Algorithm:

less than 2cm AND Stable:

• Active surveillance
• MRI/EUS every 6-12 months
• Surgery if growth documented

≥2cm OR Growing:

• Surgical resection recommended
• Rationale: 20-25% malignancy risk, metastatic potential

Surgical Approach:

• Enucleation for small, superficial lesions
• Distal pancreatectomy (preserve spleen if possible)
• Pancreaticoduodenectomy for head lesions
• Consider near-total pancreatectomy (90% resection) if multiple tumours (but risks diabetes, exocrine insufficiency)

---

C. Pituitary Adenoma Management [14]

1. Prolactinomas

Medical Management (First-Line):

• Dopamine Agonists:
  • Cabergoline: 0.25-3mg twice weekly (longer half-life, better tolerated)
  • Bromocriptine: 2.5-15mg daily (shorter half-life, more side effects)
• Mechanism: Stimulates D2 receptors → Inhibits prolactin secretion, shrinks tumour
• Efficacy: Normalizes prolactin in 80-90%, shrinks tumour in 70-80%
• MEN-1 caveat: More resistant to medical therapy than sporadic prolactinomas

Surgical Management:

• Indications: Intolerance to dopamine agonists, resistance to medical therapy, visual field defects requiring urgent decompression
• Approach: Transsphenoidal surgery (endonasal endoscopic)
• Cure rate: 50-60% (lower than sporadic due to larger size, invasiveness)

---

2. GH-Secreting Adenomas (Acromegaly)

Surgical Management (First-Line):

• Transsphenoidal surgery: Treatment of choice
• Goal: Normalize IGF-1, GH suppression to less than 1 μg/L on OGTT
• Cure rate: 60-70% for microadenomas (less than 1cm), 30-40% for macroadenomas

Medical Management:

• Indications: Persistent disease post-surgery, surgical contraindication
• Somatostatin Analogues:
  • Octreotide LAR: 20-40mg IM monthly
  • Lanreotide Autogel: 90-120mg SC monthly
  • Efficacy: Normalize IGF-1 in 50-60%
• Dopamine Agonists (Cabergoline): Adjunctive, modest efficacy
• GH Receptor Antagonist (Pegvisomant): Blocks peripheral GH action, normalizes IGF-1 in 90%

Radiotherapy:

• Indications: Residual disease after surgery + medical therapy
• Options: Stereotactic radiosurgery (Gamma Knife, CyberKnife) vs conventional fractionated
• Efficacy: 50-70% biochemical control at 10 years
• Complications: Hypopituitarism (50% at 10 years)

---

3. ACTH-Secreting Adenomas (Cushing's Disease)

Surgical Management (First-Line):

• Transsphenoidal adenomectomy
• Cure rate: 65-75% (lower if no discrete adenoma identified)

Medical Management:

• Preoperative: Control hypercortisolism
  • Ketoconazole: 400-1,200mg/day (inhibits cortisol synthesis)
  • Metyrapone: 500-6,000mg/day
  • Pasireotide (somatostatin analogue): 600-900μg SC twice daily
• Persistent disease: Consider bilateral adrenalectomy (definitive, requires lifelong glucocorticoid/mineralocorticoid replacement)

---

4. Non-Functioning Adenomas

Management:

• Macroadenomas with mass effect: Transsphenoidal surgery
• Asymptomatic: Surveillance MRI annually (surgery if growth or symptoms develop)
• Hypopituitarism: Hormone replacement (levothyroxine, hydrocortisone, sex steroids, GH if indicated)

---

D. Carcinoid Tumour Management [17]

Thymic Carcinoids

Surgical Management:

• Complete surgical resection: Only curative option
  • Median sternotomy, thymectomy + resection of invaded structures
  • Often locally invasive (pericardium, lung, pleura)
• Lymph node dissection: Mediastinal nodes

Chemotherapy:

• Adjuvant: Considered for high-grade, invasive tumours
• Metastatic disease: Platinum-based regimens (cisplatin + etoposide)

Surveillance:

• High recurrence rate (30-50%)
• CT chest every 6 months for 5 years, then annually

Prophylactic Thymectomy Debate:

• Some advocate for prophylactic thymectomy during parathyroid surgery in males (prevent thymic carcinoid)
• Controversial: Small absolute risk (2-8%), surgical morbidity, no RCT data

---

Bronchial Carcinoids

Surgical Management:

• Lobectomy or wedge resection
• Generally good prognosis

Medical Management:

• Somatostatin analogues for carcinoid syndrome

---

E. Genetic Counseling and Family Screening [2,19]

Genetic Counseling Components:

• Inheritance pattern (autosomal dominant, 50% risk to offspring)
• Clinical manifestations and natural history
• Surveillance protocols and screening benefits
• Psychological support

Cascade Screening:

• Test all first-degree relatives of probands with confirmed MEN1 mutation
• If mutation identified: Enroll in surveillance protocol from age 5-8
• If mutation not identified: Discharge from surveillance (assuming mutation detected in proband)

Prenatal/Preimplantation Genetic Diagnosis:

• Available for families with known MEN1 mutation
• Ethical considerations: Variable expressivity, management options available

Predictive Testing in Minors:

• Recommended from age 5-8 years (surveillance begins regardless of symptoms)
• Psychological assessment and support

---

11. Complications

Disease-Related Complications

Malignancy:

• Leading cause of death in MEN-1 (50% of mortality) [21]
• Pancreatic NETs: 20-25% malignant, metastasize to liver/lymph nodes
• Thymic carcinoids: Highly aggressive, 30% mortality
• Gastrinomas: 60% metastatic at diagnosis
• Bronchial carcinoids: 10-15% malignant

Osteoporosis:

• Chronic hyperparathyroidism → Bone loss
• Pathological fractures (vertebral, hip)
• Prevention: Early parathyroid surgery, calcium/vitamin D, bisphosphonates if indicated

Nephrolithiasis and Chronic Kidney Disease:

• 25-30% develop kidney stones (calcium oxalate/phosphate)
• Chronic hypercalcaemia → Nephrocalcinosis → CKD
• Prevention: Adequate hydration, control hypercalcaemia

Pituitary Apoplexy:

• Acute hemorrhage/infarction of pituitary adenoma
• Presentation: Sudden severe headache, visual loss, ophthalmoplegia, altered consciousness
• Medical emergency: Requires high-dose IV hydrocortisone, neurosurgical consultation

Hypoglycemic Seizures:

• Insulinoma → Severe hypoglycaemia
• Risk of permanent neurological damage
• Prevention: Frequent meals, prompt treatment

Gastrointestinal Complications:

• Gastrinoma: Peptic ulcers, GI bleeding, perforation, strictures
• VIPoma: Severe dehydration, acute kidney injury, electrolyte imbalance

---

Treatment-Related Complications

Parathyroid Surgery:

• Persistent/Recurrent Hyperparathyroidism: 50% at 10 years
• Permanent Hypoparathyroidism: 15-25% (requires lifelong calcium/vitamin D)
• Recurrent Laryngeal Nerve Injury: 1-5% (voice changes, aspiration)
• Hungry Bone Syndrome: Severe post-op hypocalcaemia

Pituitary Surgery:

• Hypopituitarism: 10-30% (require hormone replacement)
• Diabetes Insipidus: Transient (10-20%) or permanent (2-5%)
• CSF leak: 3-5%
• Visual deterioration: 1-2%
• Recurrence: 10-20% at 10 years

Pancreatic Surgery:

• Pancreatic Fistula: 10-30%
• Endocrine Insufficiency (Diabetes): Risk increases with extent of resection
• Exocrine Insufficiency: Requires enzyme replacement
• Surgical Mortality: less than 2% in high-volume centers

Medical Therapy:

• Dopamine Agonists: Nausea, orthostatic hypotension, impulse control disorders
• Somatostatin Analogues: Cholelithiasis (20-30%), diarrhea, hyperglycemia
• PPIs: Long-term use → Osteoporosis, hypomagnesemia, C. difficile infection

---

12. Prognosis & Outcomes

Survival Data [21,22]

• Median Age of Death: 55-60 years (vs general population life expectancy 75-80)
• 20-year Survival: 60-80% (varies by series)
• Overall Mortality: Standardized mortality ratio 2-3x general population

Causes of Death

---

Prognostic Factors [22]

Favorable:

• Early diagnosis through genetic screening
• Regular surveillance and early intervention
• Access to specialized multidisciplinary care
• Tumours less than 2cm at detection
• Low-grade (G1) pancreatic NETs
• Successful surgical resection of functional tumours

Unfavorable:

• Pancreatic NETs > 3cm (higher metastatic risk)
• Thymic carcinoid (especially in males)
• Metastatic disease at presentation
• High Ki-67 proliferation index (> 5%)
• Lymph node involvement
• Delayed diagnosis

---

Quality of Life Considerations

• Chronic Disease Burden: Lifelong surveillance, multiple surgeries
• Psychological Impact: Anxiety, depression, genetic implications for children
• Treatment Side Effects: Hypoparathyroidism, hypopituitarism, diabetes (post-pancreatectomy)
• Financial Burden: Frequent imaging, specialist consultations, medications
• Reproductive Concerns: Genetic counseling, prenatal testing

Support Resources:

• MEN-1 patient support groups
• Genetic counseling services
• Psychological support
• Specialized endocrine centers

---

13. Special Populations

MEN-1 in Pregnancy [23]

Preconception Counseling:

• 50% risk of transmission to offspring
• Optimize endocrine function (normalize calcium, prolactin)
• Assess pituitary mass effect (risk of expansion during pregnancy)
• Genetic counseling regarding prenatal/preimplantation diagnosis

Pregnancy Considerations:

Hyperparathyroidism:

• Maternal hypercalcaemia → Fetal hypocalcaemia (suppressed fetal parathyroids)
• Neonatal tetany, bone demineralization
• Management: Parathyroid surgery ideally in 2nd trimester if symptomatic or Ca > 2.85 mmol/L
• Conservative: Hydration, low-calcium diet (limited efficacy)

Prolactinomas:

• Risk of tumour expansion (especially macroadenomas): 5% for microadenomas, 20-30% for macroadenomas
• Management:
  • Cabergoline: Discontinue once pregnancy confirmed (safety data limited but reassuring)
  • Monitor symptoms (headaches, visual changes) monthly
  • Visual field testing each trimester if macroadenoma
  • Restart cabergoline if symptomatic expansion
• Breastfeeding: Generally safe to resume dopamine agonist if needed

Insulinomas:

• Pregnancy increases insulin resistance → May mask hypoglycemia
• Frequent glucose monitoring
• Surgical resection in 2nd trimester if uncontrolled

Gastrinomas:

• PPIs generally safe in pregnancy (Category B/C depending on agent)
• Continue treatment for symptom control

---

Pediatric MEN-1

Onset:

• Rare before age 5
• Hyperparathyroidism typically first manifestation (median age 20-25 but can occur in teens)

Surveillance Initiation:

• Begin biochemical screening age 5-8
• Imaging (MRI pituitary) age 5
• MRI abdomen, CT chest age 10-15 (depending on protocol)

Psychosocial Considerations:

• Age-appropriate disclosure of diagnosis
• Impact on family dynamics
• Transition to adult care

---

14. Evidence & Guidelines

Major Clinical Practice Guidelines

1. Endocrine Society Clinical Practice Guideline (2012) [2]

   • Comprehensive management recommendations
   • Surveillance protocols by age
   • Genetic testing indications

2. European Neuroendocrine Tumor Society (ENETS) Guidelines [20]

   • Pancreatic NET management
   • Imaging modalities
   • Surgical thresholds

3. American Association of Clinical Endocrinologists (AACE) [19]

   • Endocrine tumor surveillance
   • Biochemical screening intervals

---

15. Patient & Layperson Explanation

What is MEN-1?

MEN-1 stands for "Multiple Endocrine Neoplasia Type 1." It's a rare genetic condition that runs in families. If you have MEN-1, you have a higher chance of developing tumours (usually benign, not cancer) in certain hormone-producing glands in your body.

The main glands affected are the "3 Ps":

1. Parathyroid (in your neck): These small glands control calcium levels in your blood.
2. Pituitary (in your brain): This pea-sized gland controls many other hormones.
3. Pancreas (in your abdomen): This organ helps digest food and controls blood sugar.

How do I get MEN-1?

MEN-1 is caused by a change (called a "mutation") in a gene called MEN1. You inherit this from one of your parents, like eye colour or height. If you have MEN-1:

• There's a 50% chance you'll pass it to each of your children.
• Not everyone in the family gets the same tumours or at the same age.

Is it cancer?

Most of the tumours in MEN-1 are benign (not cancer). However, they can still cause problems:

• They may produce too much hormone (e.g., too much calcium causing kidney stones, or too much acid causing stomach ulcers).
• They can grow large and press on nearby organs.
• Some tumours (especially in the pancreas) can become cancerous or spread, which is why doctors monitor you closely.

What are the symptoms?

Symptoms depend on which gland is affected:

Parathyroid (too much calcium):

• Kidney stones
• Weak bones (fractures)
• Feeling tired, depressed
• Stomach pain, nausea

Pituitary:

• Women: Missed periods, milky breast discharge
• Men: Sexual problems, enlarged hands/feet (if growth hormone)
• Headaches, vision problems (if tumour is large)

Pancreas:

• Insulinoma (too much insulin): Shaking, sweating, confusion when hungry (low blood sugar)
• Gastrinoma (too much acid): Severe heartburn, stomach ulcers, diarrhea

Many people have no symptoms early on and are diagnosed through family screening.

How is it diagnosed?

1. Blood tests: Check hormone levels (calcium, prolactin, insulin, etc.)
2. Genetic test: Looks for the MEN1 gene mutation in your DNA (a simple blood or saliva test)
3. Scans: MRI or CT scans to look for tumours in glands

If a family member has MEN-1, your doctor can test you and your relatives.

How is it treated?

There's no cure for the genetic condition, but we can treat the tumours:

Parathyroid:

• Surgery to remove 3-4 overactive glands (leave a small piece to prevent calcium levels from dropping too low)

Pituitary:

• Prolactin tumours: Tablets (dopamine agonists) usually shrink them
• Other tumours: Surgery through the nose to reach the brain

Pancreas:

• Insulinoma: Surgery to remove the tumour
• Gastrinoma: Strong acid-blocking tablets (PPIs), sometimes surgery
• Non-functional tumours: Watch with scans, surgery if they grow large (> 2cm)

Do I need regular check-ups?

Yes, lifelong surveillance is essential:

• Blood tests: Once a year to check hormone levels
• Scans (MRI, CT): Every 1-2 years to look for new tumours
• This saves lives: Finding tumours early makes them easier to treat

What's the outlook?

With modern care, most people with MEN-1 live into their 50s-70s. The key is:

• Early diagnosis through family screening
• Regular monitoring to catch tumours when they're small
• Working with a specialist team (endocrinologists, surgeons, geneticists)

Important message: MEN-1 is a lifelong condition, but with the right care, you can manage it and live well.

Where can I get support?

• Ask your doctor about MEN-1 patient support groups
• Genetic counselors can help with family planning
• National organizations (e.g., AMEND - Association for Multiple Endocrine Neoplasia Disorders)

---

16. Viva Questions & Model Answers

---

17. Clinical Pearls

Pearl 1: Hyperparathyroidism less than 40 years = Think Genetic Syndrome

• Sporadic primary hyperparathyroidism median age 55-60
• MEN-1, MEN-2A, Familial Isolated Hyperparathyroidism, Hyperparathyroidism-Jaw Tumour Syndrome all present younger
• Always take family history

Pearl 2: Multiple Pancreatic NETs = MEN-1 Until Proven Otherwise

• Sporadic pancreatic NETs are usually solitary
• Multiple lesions on imaging should prompt MEN1 genetic testing

Pearl 3: Facial Angiofibromas Can Precede Endocrine Tumours

• Present in 80% of MEN-1 patients
• May appear in teens/20s before hyperparathyroidism
• Important diagnostic clue

Pearl 4: Thymic Carcinoids in Males Are Highly Lethal

• 30% mortality
• Some advocate prophylactic thymectomy during parathyroid surgery in males
• Debate ongoing (no RCT evidence)

Pearl 5: MEN-1 Pituitary Adenomas Are More Aggressive

• Larger, more invasive, more resistant to medical therapy than sporadic
• Higher recurrence post-surgery

Pearl 6: Gastrinomas in MEN-1 Are Often Duodenal, Not Pancreatic

• 70% duodenal (multiple, small, in "gastrinoma triangle")
• Require careful duodenotomy + transillumination to identify
• Pancreatic gastrinomas more common in sporadic Zollinger-Ellison

Pearl 7: Surveillance Saves Lives

• Early detection of pancreatic NETs at less than 2cm → 5-year survival > 90%
• Detection at > 3cm or metastatic → 5-year survival 50-60%

---

18. References

1. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1-2):2-15. doi:10.1016/j.mce.2013.08.002

2. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011. doi:10.1210/jc.2012-1230

3. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658-5671. doi:10.1210/jcem.86.12.8070

4. Goudet P, Dalac A, Le Bras M, et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015;100(4):1568-1577. doi:10.1210/jc.2014-3659

5. Stratakis CA, Schussheim DH, Freedman SM, et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2000;85(12):4776-4780. doi:10.1210/jcem.85.12.7064

6. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404-407. doi:10.1126/science.276.5311.404

7. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29(1):22-32. doi:10.1002/humu.20605

8. Thevenon J, Bourredjem A, Faivre L, et al. Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'étude des Tumeurs Endocrines (GTE) cohort study. Hum Mol Genet. 2013;22(10):1940-1948. doi:10.1093/hmg/ddt039

9. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820-823. doi:10.1073/pnas.68.4.820

10. Matkar S, Thiel A, Hua X. Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem Sci. 2013;38(8):394-402. doi:10.1016/j.tibs.2013.05.005

11. Tonelli F, Spini S, Tommasi M, et al. Intraoperative parathormone measurement in patients with multiple endocrine neoplasia type I syndrome and hyperparathyroidism. World J Surg. 2000;24(5):556-562. doi:10.1007/s002689910091

12. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113(7 Suppl):1807-1843. doi:10.1002/cncr.23648

13. Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg. 2006;243(2):265-272. doi:10.1097/01.sla.0000197959.70820.15

14. Scheithauer BW, Laws ER Jr, Kovacs K, Horvath E, Randall RV, Carney JA. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol. 1987;4(3):205-211. PMID:3313592

15. Gatta-Cherifi B, Chabre O, Murat A, et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'étude des Tumeurs Endocrines database. Eur J Endocrinol. 2012;166(2):269-279. doi:10.1530/EJE-11-0679

16. Anlauf M, Garbrecht N, Henopp T, et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol. 2006;12(34):5440-5446. doi:10.3748/wjg.v12.i34.5440

17. Ferolla P, Falchetti A, Filosso P, et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab. 2005;90(5):2603-2609. doi:10.1210/jc.2004-2155

18. Asgharian B, Turner ML, Gibril F, et al. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab. 2004;89(11):5328-5336. doi:10.1210/jc.2004-0218

19. Falchetti A, Marini F, Luzi E, Tonelli F, Brandi ML. Multiple endocrine neoplasms. Best Pract Res Clin Rheumatol. 2008;22(1):149-163. doi:10.1016/j.berh.2007.11.011

20. Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98-119. doi:10.1159/000335591

21. Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Étude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34(2):249-255. doi:10.1007/s00268-009-0290-1

22. Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore). 2013;92(3):135-181. doi:10.1097/MD.0b013e3182954af1

23. Caimari F, Valassi E, Garbayo P, et al. Cushing's syndrome and pregnancy outcomes: a systematic review of published cases. Endocrine. 2017;55(2):555-563. doi:10.1007/s12020-016-1117-0

---

Last Updated: 2025-01-05 Next Review: 2026-01-05 Authors: MedVellum Medical Education Team